Life Sciences

Westborough-based RXi Pharmaceuticals Corp., a clinical-phase biotechnology company focusing on RNA-target technology, has filed an application for listing on The NASDAQ Capital Market.

On-the-job mistakes always impact the bottom line, but the degree of expense varies widely from industry to industry.

Marlborough-based Sunovion Pharmaceuticals announced it has secured U.S. Food and Drug Administration approval for two new uses of its Latuda drug.

Despite annual losses, Arrhythmia Research Technologies of Fitchburg posted revenue gains in the first quarter of 2013, according to an earnings statement.

Boston Scientific of Natick has agreed to buy the Lowell-based electrophysiology business of C.R. Bard for $275 million in cash, the company announced today.

Devens-based Bionostics Inc. has agreed to be acquired for $104 million in cash, according to Minnesota-based Techne Corp.

Global pharmaceutical giant AstraZeneca, which has a manufacturing facility in Westborough, said it has agreed to buy Pearl Therapeutics, a privately held company in Redwood City, Calif., that focuses on the development of inhaled, small-molecule drugs for chronic obstructive pulmonary disease, or COPD.

Citing several challenges over 2012, Fitchburg-based medical device manufacturing and software firm Arrhythmia Research Technology Inc. last...

Westborough-based RXi Pharmaceuticals said the first double-blind study of its anti-scarring treatment using healthy volunteers had positive results.

Spring Bank Pharmaceuticals of Milford said it has begun dosing in a Phase I clinical study of its drug for patients with Hepatitis C.